Pulmonx Corporation will present at Wells Fargo and Lake Street investor conferences in September 2025.
Quiver AI Summary
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, announced its participation in two upcoming investor conferences: a fireside chat at the Wells Fargo Healthcare Conference on September 4 in Boston and 1x1 meetings at the Lake Street Best Ideas Growth Conference on September 11 in New York. A live and archived webcast of the fireside chat will be accessible on the company's website. Pulmonx is known for its innovative technologies, including the FDA-approved Zephyr® Endobronchial Valve, which is utilized worldwide to treat severe emphysema and improve quality of life for patients. For further details, the public can visit the Pulmonx website.
Potential Positives
- The announcement of management's participation in multiple investor conferences highlights Pulmonx's commitment to engaging with the investment community, potentially increasing visibility and investor interest.
- The company’s products, particularly the Zephyr® Endobronchial Valve, are recognized as a standard of care treatment option for severe emphysema, reinforcing Pulmonx's leadership position in the market.
- Receiving FDA pre-market approval for the Zephyr Valve as a “breakthrough device” underscores the innovative nature of Pulmonx's offerings and their significance in addressing unmet medical needs.
- The availability of a live and archived webcast for the fireside chat enhances transparency and accessibility for investors, which can foster trust and potentially lead to increased investment.
Potential Negatives
- None
FAQ
What investor conferences will Pulmonx be presenting at?
Pulmonx will present at the Wells Fargo Healthcare Conference and the Lake Street Best Ideas Growth Conference.
When is the Wells Fargo Healthcare Conference?
The Wells Fargo Healthcare Conference is scheduled for Thursday, September 4, 2025, at 1:30 pm PT.
How can I access the webcast of the Pulmonx fireside chat?
A live and archived webcast of the fireside chat will be available on the "Investors" section of the Pulmonx website.
What products does Pulmonx offer for lung disease treatment?
Pulmonx offers products like the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Reports.
Where is the Zephyr Valve commercially available?
The Zephyr Valve is commercially available in more than 25 countries globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LUNG Insider Trading Activity
$LUNG insiders have traded $LUNG stock on the open market 28 times in the past 6 months. Of those trades, 1 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $LUNG stock by insiders over the last 6 months:
- STEVEN S. WILLIAMSON (PRESIDENT AND CEO) has made 0 purchases and 3 sales selling 37,612 shares for an estimated $228,758.
- DAVID AARON LEHMAN (GENERAL COUNSEL) has made 0 purchases and 10 sales selling 32,812 shares for an estimated $203,656.
- GLENDON E. III FRENCH sold 20,000 shares for an estimated $157,000
- MEHUL JOSHI (Chief Financial Officer & PAO) has made 0 purchases and 3 sales selling 22,445 shares for an estimated $127,645.
- DANIEL P FLORIN purchased 23,321 shares for an estimated $71,362
- GEOFFREY BERAN ROSE (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 9 sales selling 12,726 shares for an estimated $62,941.
- RICHARD FERRARI sold 8,000 shares for an estimated $25,280
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LUNG Hedge Fund Activity
We have seen 57 institutional investors add shares of $LUNG stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,575,901 shares (-45.5%) from their portfolio in Q2 2025, for an estimated $4,081,583
- FMR LLC removed 1,156,888 shares (-21.4%) from their portfolio in Q2 2025, for an estimated $2,996,339
- MILLENNIUM MANAGEMENT LLC added 958,048 shares (+459.5%) to their portfolio in Q2 2025, for an estimated $2,481,344
- ALTIUM CAPITAL MANAGEMENT LLC removed 815,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $5,484,950
- GSA CAPITAL PARTNERS LLP added 423,725 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,097,447
- KENT LAKE PR LLC removed 418,434 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,816,060
- BANK OF AMERICA CORP /DE/ added 407,971 shares (+556.6%) to their portfolio in Q2 2025, for an estimated $1,056,644
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LUNG Analyst Ratings
Wall Street analysts have issued reports on $LUNG in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 07/31/2025
- D. Boral Capital issued a "Buy" rating on 07/31/2025
- Lake Street issued a "Buy" rating on 07/31/2025
- Canaccord Genuity issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for $LUNG, check out Quiver Quantitative's $LUNG forecast page.
$LUNG Price Targets
Multiple analysts have issued price targets for $LUNG recently. We have seen 7 analysts offer price targets for $LUNG in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Larry Biegelsen from Wells Fargo set a target price of $3.0 on 08/01/2025
- Jason Bednar from Piper Sandler set a target price of $2.5 on 07/31/2025
- Rick Wise from Stifel set a target price of $5.0 on 07/31/2025
- Jason Kolbert from D. Boral Capital set a target price of $16.0 on 07/31/2025
- Frank Takkinen from Lake Street set a target price of $8.0 on 07/31/2025
- Joanne Wuensch from Citigroup set a target price of $4.15 on 05/22/2025
- Jon Young from Canaccord Genuity set a target price of $15.0 on 05/01/2025
Full Release
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference
Format:
Fireside Chat and 1x1 meetings
Date:
Thursday, September 4 at 1:30 pm PT/ 4:30 pm ET
Location:
Boston, MA
Webcast Link:
Click here
Lake Street Best Ideas Growth (BIG9) Conference
Format:
1x1 meetings
Date:
Thursday, September 11
Location:
New York, NY
A live and archived webcast of the fireside chat will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX™ Platform, and StratX
®
Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx ® , AeriSeal ® , Chartis ® , StratX ® , and Zephyr ® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
[email protected]
